Baricitinib

CAS 1187594-09-7 7 current recordsSmall Molecule

Who holds supplier records for Baricitinib? 7 organisations hold a current record for Baricitinib: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (2), China (1) and Poland (1); not recorded for 3.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Baricitinib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/baricitinib

Reading the evidence

  • 7 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 4 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Baricitinib expires 30 Nov 2032. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (7)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Baricitinib. Country is the organisation's recorded country, not necessarily the manufacturing site.

India2China1Poland1Country not recorded for 3
  • APITORIA PHARMA PRIVATE LTD
    Active DMF 36598 · latest filing Dec 2021
    India Company GMP cert on record
  • CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD
    Active DMF 36030 · latest filing Aug 2021
    Company GMP cert on record
  • MSN Laboratories Private Limited
    Active DMF 35340 · latest filing Nov 2020
    India Company GMP cert on record
  • NANJING LIBRAVO PHARMACEUTICAL CO LTD
    Active DMF 37244 · latest filing Aug 2022
  • SABA ILAC SANAYI VE TICARET AS
    Active DMF 44292 · latest filing Jul 2026
  • Wisdom Pharmaceutical Co., Ltd
    Active DMF 36732 · latest filing Jan 2022
    China
  • Zakłady Farmaceutyczne Polpharma S.A.
    Active DMF 39562 · latest filing Dec 2024
    Poland Company GMP cert on record
Need Baricitinib sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (6 listed products contain Baricitinib). The latest listed patent expires 30 Nov 2032. The latest listed exclusivity runs to 25 Sept 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Baricitinib is a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis. It is also under investigation for other autoimmune and inflammatory conditions.

Chemical identity

IUPAC name
2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
Canonical SMILES
CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
InChIKey
XUZMWHLSFXCVMG-UHFFFAOYSA-N
Synonyms
Olumiant API, incb-028050, incb028050, ly-3009104, ly3009104, olumiant

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Janus Kinase Inhibitor
Mechanism of action
Janus Kinase Inhibitors

Therapeutic areas

RheumatologyImmunologyDermatology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Baricitinib?

7 organisations hold an active US FDA Type II Drug Master File or a CEP for Baricitinib: APITORIA PHARMA PRIVATE LTD (India), CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD, MSN Laboratories Private Limited (India), NANJING LIBRAVO PHARMACEUTICAL CO LTD, SABA ILAC SANAYI VE TICARET AS, Wisdom Pharmaceutical Co., Ltd (China) and Zakłady Farmaceutyczne Polpharma S.A. (Poland). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Baricitinib Drug Master Files are active?

APITORIA PHARMA PRIVATE LTD (DMF 36598), CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD (DMF 36030), MSN Laboratories Private Limited (DMF 35340), NANJING LIBRAVO PHARMACEUTICAL CO LTD (DMF 37244), SABA ILAC SANAYI VE TICARET AS (DMF 44292), Wisdom Pharmaceutical Co., Ltd (DMF 36732) and Zakłady Farmaceutyczne Polpharma S.A. (DMF 39562). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does the FDA Orange Book list patents for products containing Baricitinib?

Yes. The latest patent listed for an approved US product containing Baricitinib expires 30 Nov 2032, across 6 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Baricitinib supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Baricitinib?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.